Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Phibro Animal Health Corporation (PAHC) vs Pacira BioSciences, Inc. (PCRX)

Phibro Animal Health Corporation and Pacira BioSciences, Inc. are both Drug Manufacturers Specialty & Generic companies. Phibro Animal Health Corporation is the larger, with a market value of $1.4B against $1.0B — 1.4× the size. Phibro Animal Health Corporation trades at the lower P/E: 14.0× against 71.8×. Phibro Animal Health Corporation grew revenue faster over the last twelve months: 17.1% against 5.71%. Phibro Animal Health Corporation has the higher net margin (6.57% vs 1.96%) and the higher return on invested capital (11.7% vs 1.58%). Across the 22 metrics below, Phibro Animal Health Corporation leads on 13 and Pacira BioSciences, Inc. on 9.

Valuation

Metric PAHC PCRX Drug Manufacturers Specialty & Generic median
P/E 14.00 71.77 20.14
P/S 0.92 1.33 2.25
P/B 3.62 1.48 1.90
Price to free cash flow 141.58 5.52 16.54
EV/EBITDA 8.25 12.68 12.29
EV/Sales 1.35 1.75 2.56
Earnings yield 7.14% 1.39% (2.99%)
Free cash flow yield 0.71% 18.11% 0.00%

Profitability

Metric PAHC PCRX Drug Manufacturers Specialty & Generic median
Gross margin 33.76% 79.21% 53.94%
Operating margin 12.81% 2.66% 0.00%
Net margin 6.57% 1.96% 0.00%
Free cash flow margin 0.65% 24.06% 0.00%
Return on equity 29.72% 2.05% (0.40%)
Return on assets 6.97% 1.05% (3.32%)
Return on invested capital 11.72% 1.58% 0.00%

Growth

Metric PAHC PCRX Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) 17.12% 5.71% 10.01%
EPS growth (last fiscal year) 104.20% 107.44% —
Revenue growth, 5-year CAGR 12.74% 11.07% 6.74%
Net income growth, 5-year CAGR 12.89% (45.44%) 0.00%

Health

Metric PAHC PCRX Drug Manufacturers Specialty & Generic median
Debt to equity 1.90 0.54 0.05
Current ratio 2.96 5.04 2.31
Net debt to EBITDA 2.62 1.24 0.85

Dividend

Metric PAHC PCRX Drug Manufacturers Specialty & Generic median
Dividend yield 4.19% — 1.70%
Payout ratio 0.59 0.00 0.00

Size

Metric PAHC PCRX Drug Manufacturers Specialty & Generic median
Market cap 1.38b 1.02b 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack